
Relmada Therapeutics Inc is a biotechnology business based in the US. Relmada Therapeutics shares (RLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Relmada Therapeutics employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Relmada Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RLMD – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Relmada Therapeutics stock price (NASDAQ: RLMD)
Use our graph to track the performance of RLMD stocks over time.Relmada Therapeutics shares at a glance
Latest market close | $18.99 |
---|---|
52-week range | $15.74 - $35.35 |
50-day moving average | $21.11 |
200-day moving average | $22.10 |
Wall St. target price | $59.71 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-6.99 |
Buy Relmada Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Relmada Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Relmada Therapeutics price performance over time
Historical closes compared with the close of $18.99 from 2022-06-30
1 week (2022-06-24) | -3.36% |
---|---|
1 month (2022-06-02) | 1.77% |
3 months (2022-03-31) | -29.64% |
6 months (2021-12-31) | -15.71% |
1 year (2021-07-02) | -41.77% |
---|---|
2 years (2020-07-02) | -55.61% |
3 years (2019-07-02) | 955.00% |
5 years (2017-06-30) | 2,215.85% |
Relmada Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -53.69% |
Return on equity TTM | -95.03% |
Profit margin | 0% |
Book value | $7.16 |
Market capitalisation | $589.6 million |
TTM: trailing 12 months
Relmada Therapeutics share dividends
We're not expecting Relmada Therapeutics to pay a dividend over the next 12 months.
Have Relmada Therapeutics's shares ever split?
Relmada Therapeutics's shares were split on a 1:4 basis on 29 September 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Relmada Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Relmada Therapeutics shares which in turn could have impacted Relmada Therapeutics's share price.
Relmada Therapeutics share price volatility
Over the last 12 months, Relmada Therapeutics's shares have ranged in value from as little as $15.735 up to $35.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Relmada Therapeutics's is 0.5422. This would suggest that Relmada Therapeutics's shares are less volatile than average (for this exchange).
Relmada Therapeutics overview
Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida. .
Relmada Therapeutics in the news
Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
Frequently asked questions
What percentage of Relmada Therapeutics is owned by insiders or institutions?Currently 1.295% of Relmada Therapeutics shares are held by insiders and 77.969% by institutions. How many people work for Relmada Therapeutics?
Latest data suggests 10 work at Relmada Therapeutics. When does the fiscal year end for Relmada Therapeutics?
Relmada Therapeutics's fiscal year ends in June. Where is Relmada Therapeutics based?
Relmada Therapeutics's address is: 2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134 What is Relmada Therapeutics's ISIN number?
Relmada Therapeutics's international securities identification number is: US75955J4022 What is Relmada Therapeutics's CUSIP number?
Relmada Therapeutics's Committee on Uniform Securities Identification Procedures number is: 134010107
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert